Information, Litigation, and Common Law Evolution
American Law and Economics Review, Vol. 8, No. 1, pp. 33-61, 2006
34 Pages Posted: 25 Apr 2005
There are 2 versions of this paper
Information, Litigation, and Common Law Evolution
Information, Litigation, and Common Law Evolution
Abstract
It is common in the legal academy to describe trends in judicial decisions leading to new common law rules as the result of conscious judicial effort. Evolutionary models of litigation, in contrast, treat common law as resulting from pressure applied by litigants. One apparent difficulty in the theory of litigation is explaining how trends in judicial decisions favoring one litigant, and biasing the legal standard, could occur. This paper presents a model in which an apparent bias in the legal standard can occur in the absence of any effort toward this end on the part of judges. Trends can develop favoring the better informed litigant whose case is also meritorious. Although the model does not suggest an unambiguous trend toward efficient legal rules, it does show how private information from litigants becomes embodied in common law, an important part of the theory of efficient legal rules.
Keywords: common law evolution, common law rules, theory of litigation, litigation, torts, litigation procedure, decisions biasing the legal standard, theory of efficient legal rules
JEL Classification: K00, K13, K42
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
Paying for Delay: Pharmaceutical Patent Settlement as a Regulatory Design Problem
-
An Aggregate Approach to Antitrust: Using New Data and Rulemaking to Preserve Drug Competition
-
Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals
-
The Economics of Injunctive and Reverse Settlements
By Keith N. Hylton and Sungjoon Cho
-
Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry
By Lee Branstetter, Chirantan Chatterjee, ...
-
Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets